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Abstract: Two baboon liver xenografts transplanted to patients with B virus 
hepatitis supported life for 70 and 26 days but did not function optimally 
despite minimum or no histopathologic findings of overt h~moral or 
cellular rejection in serial biopsies. However, there was eVidence of 
complement activation in both cases, which in retrospect was thought to 
explain the unsatisfactory outcome. Strategies to deal with this problem are 
discussed. 
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Introduction 
In June 1992 and January 1993, we made attempts 
at baboon-to-human liver xenotransplantation, both 
of which failed after 70 and 26 days. The patients 
whose original disease was B hepatitis had no evi-
dence of viral reinfection during their posttransplant 
survival. and there was little histopathologic evi-
dence of conventional humoral or cellular rejection 
of these livers. The clinical courses have been pub-
lished in detail elsewhere [1,21, including the infec-
tious complications that were the immediate causes 
of death: ruptured mycotic intracerebral aneurysm 
caused by aspergillus in Case I, and peritonitis, sec-
ondary to an anastomotic leak at the jejuno-
jejunostomy of the Roux-y biliary reconstruction, in 
Case 2. However, the underlying reason for failure 
in both cases was suboptimal xenograft function. 
which has not been satisfactorily explained. 
Surgical procedures 
The techniques were adapted from hepatic allo-
transplantation and seemed satisfactory. The body. 
weights of the baboon donors were only 40% at 
those of the recipients. necessitating the so-called 
piggyback operation that leaves the recipient vena 
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cava intact (Fig. 1). The livers regenerated up to 
optimal volume for recipient size in both cases. 
Biopsies showed multitudes of proliferating hepa-
tocytes and duct cells. There were almost no in-
filtrating immunocytes. The interesting possibility 
has been raised recently by the studies of 
Shiraishi et aL [3] that the use of small-to-Iarge 
liver allografts (and by inference xenografts) un-
wittingly introduces an augmented antigenicity 
factor. In such circumstances. the increased MHC 
Class II expression that is independently associ-
ated with liver regeneration [4) appeared to be 
responsible for much more severe cellular and 
humoral rejections than seen with size-matched 
liver transplantation in the same rat strains. 
Murase had independently made the same obser-
vations in our laboratory (Table I). 
Preoperative status 
The conventional Iymphocytotoxic crossmatch of 
the recipient sera with their donor lymphocytes was 
positive initially but negative after dithiothreitol 
(OTT) treatment. meaning that the anti bodies were 
largely IgM. Postoperatively, even the conventional 
crossmatches became negative. Both patients had 
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Fig. 1. Piggyback operation used for both baboon-to-human 
xenotransplantations. 
donors of their own blood type. A to A in Case 1. 
and B to B in Case 2. They were immune compe-
tent with in vitro testing. although Patient 1 had as-
ymptomatic HIV infection. and had undergone 
posttraumatic splenectomy 3 years previously. This 
patient was half the age (35 years) of Patient 2 and 
far less frail. Patient 2 had developed deep hepatic 
coma and was on a ventilator. 
Postoperative courses 
The first patient awoke promptly from anesthesia. 
resumed diet and ambulation, and became jaundice-
free for most of the 70 days of survival. However. 
his alkaline phosphatase was elevated from the sec-
ond week onward. suggesting partial biliary obstruc-
tion. At autopsy after 70 days. the entire biliary tree 
was filled with inspissated bile. and most of the bil-
iary ducts. which by this time had become bile lakes. 
were denuded of epithelium. 
The second patient never woke from his pre-
existing coma, and in contrast to the first one failed 
to become anicteric. Again. the allograft at autopsy 
was filled with inspissated bile. Having the same 
cholestatic problem twice without clear evidence of 
mechanical obstruction raised the possibility that the 
baboon liver produced a lithogenic bile in the 
human environment. Although this kind of meta-
bolic incompatibility has not been absolutely ruled 
out, it does not seem likely in view of other physi-
ologic evidence of hepatic dysfunction. Neither pa-
tient was able to maintain a postoperative serum 
albumin above 2 gm%. Both patients developed 
renal failure. 
Pathologic observations 
The disparity between the paucity of the histopatho-
logic abnormalities, and the discouraging functional 
deficiencies of these transplants suggested incom-
plete control of xenograft rejection. Nearly 30 years 
ago, six baboon kidney xenografts were transplanted 
to patients treated with azathioprine-prednisone im-
munosuppression. The organs functioned for 6 to 60 
days [5]. At the end, the baboon kidney xenografts 
had fierce cellular rejection. However. the key find-
ing was a presumably antibody-mediated (humoral) 
occlusive endothelialitis of the graft vessels that 
choked off much of the arterial supply. The conse-
quent distal ischemia appeared to be responsible for 
patchy gangrene of the xenografts. interspersed be-
tween islands of still-functional parenchyma. Simi-
lar gross and histopathologic findings were reported 
more than 20 years later by Bailey after cardiac 
xenotransplantation under a cyclosporine-based im-
munosuppressive regimen (the Baby Fae case) [6]. 
In contrast. the two liver xenografts treated with 
a four-drug immunosuppressive cocktail (FK 506. 
prednisone. prostaglandin E I , and cyclophospha-
mide) had little or no evidence of cellular rejection 
in biopsies obtained over the 70 and 26 days of sur-
Table 1. The effect of 70% donor hepatectomy 1 day before liver transplantationa 
Donor hepatectomy 
Donor -+ Recipient (-24 hours) n Survival (days) Median (days) 
LEW -+ BN No 10 23. 23. 23. 25. 28. 28.5 
29.29.30.32.37 
Yes 5 7.8,9.11.12 9.0 
JThe reCIpient animals received no Immunosuppression. The role of releCtlOn was established by histopathologic studies. and by control 
experiments showing that the hepatectomy effect could be abolished by a slOg Ie dose of FK 506 (·1 mg/kg 1M) on the day of 
transplantation. 
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vival. The patient with the longest follow-up had a 
mild focal cellular rejection on day 12 by the con-
ventional criteria used for hepatic allografts. On day 
64 there was a mild but diffuse increase in T (CD3+) 
and NK (Leu-7+) cells in the sinusoids and septal 
bile ducts but the findings were insufficient for an 
unequivocal diagnosis of rejection. There was some 
centrilobular hepatocyte drop out. No definite evi-
dence of cellular rejection was seen in any of the 
seven biopsy samples taken from Patient 2 over a 
26-day period. Both xenografts were entirely free 
of the arteritis that has been associated with vascu-
lar rejection in all previous baboon to human kid-
ney or heart grafts. Nevertheless. sludging as well 
as the presence of polymorphonuclear leukocytes 
was seen in the sinusoids of the xenografts imme-
diately after reperfusion. compatible with the diag-
nosis of an aborted hyperacute rejection. 
Striking microchimerism of the kind associated 
with successful liver allotransplantation [7] was evi-
dent throughout life and at autopsy in both patients 
[1,2]. Because the first received only a liver, baboon 
DNA found by PCR in essentially all tissues re-
trieved at autopsy at 70 days were apparently chi-
meric nonparenchymal cells (NPCs). In addition to 
the liver, Patient 2 was given a large dose of 
unpurged bone marrow cells (3 x 1 l~ /kg body 
weight) perioperatively. He also had mixed xeno-
geneic chimerism at all times until death. 
The question of complement activation Injury 
rn both patients. total complement was depleted for 
most of the critical first 2 weeks while complement 
components C. C4, and C~ became undetectable [11. 
During this time. circulating immune complexes 
appeared. This complement evolution was similar 
to that reported previously in recipients of allografts 
transplanted across a positive lymphocytotoxic 
crossmatch [8]. After 10 days, the complement sys-
tem settled down but irreversible damage may have 
occurred. Although the xenografts had little evi-
dence of cellular or vascular rejection. they exhib-
ited a very fine microsteatosis on their first biopsies 
that became obvious within a few days. particularly 
in Case 2 [1.2]. This finding has been reported in 
cases of allotransplantation with inexplicable pri-
mary hepatic nonfunction. Although these findings 
receded. the microsteatosis is suspected to represent 
a sublethal injury that precluded long term success 
in either case. There was prompt binding of IgM and 
rgG in the grafts. The IgM but not the IgG largely 
disappeared from the graft tissues In later biopsies. 
The relationship of these tindings to those of hy-
peracute allograft rejection has nOl been proved. but 
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we believe that these livers were acutely damaged 
by an incomplete version of the kind of rejection 
first described in ABO incompatible kidney recipi-
ents [9] and subsequently in patients with a posi-
tive lymphocytotoxic crossmatch (10,111. Although 
these syndromes usually are associated with anti-
graft antibodies, this is not an absolute requirement 
[12,13]. The antibody versus nonantibody distinc-
tion in cases of hyperacute rejection described in the 
first instance the classical pathway of complement 
activation in which the first steps are antibody-
dependent. and in the second, the alternative path-
way, which does not require an antibody trigger or 
the participation of complement components Ct. C2• 
and C4• The consequent hyperacute allograft rejec-
tion syndromes with or without preformed antigraft 
antibodies are not thought by us to be fundamen-
tally different from those seen after xenotransplan-
tation of organs between genetically diverse species 
[1,2]. We postulate that our baboon xenografts 
suffered damage by similar but less obvious mech-
anistic events. 
Control of complement activation: Back to the laboratory 
Anticomplement strategies 
The complement pathogenicity that derives from the 
cleavage products of C3 and Cs has been effectively 
mitigated (but not eliminated with cobra venom 
(which depletes C3 and Cs), and soluble recombi-
nant complement receptor Type I. which binds to the 
cleavage fragments of C, and Cs, preventing ampli-
fication through C1b. However, binding to the 
anaphylatoxins C3a and Csa prevents another mecha-
nism of complement injury-the activation of mast 
cells, polymorphonuclear leukocytes. and other 
sources of soluble inflammatory mediators such as 
platelet-activating factor [14,15]. Thus. cobra venom 
and the soluble complement receptor I impede by 
different mechanisms both the classical or alterna-
tive cascades. By shutting off both pathways, such 
agents can interdict or ameliorate temporarily the 
Arthus reaction. Shwartzman reaction. and neutro-
phil-mediated tissue injury. 
Another interesting anticomplement drug is a ses-
quiterpene compound called K76. which is produced 
by a species of fungi imperfecti found in the soil of 
one of the Okinawa islands. This drug blocks the 
Cs step of complement activation and also acceler-
ates the decay of Csb, just proximal to the forma-
tion of the membrane attack complex (MAC) 
formed by complement components 5-9 in both the 
classical and alternative pathways of complement 
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activation (16). K76 has been used with another 
drug called FUT (a synthetic inhibitor of serine pro-
teases) that had a small therapeutic effect by itself. 
K76 and FUT together allowed guinea pig heart 
graft survival in rats for 100 min (16). 
We obtained a small supply of K76. which. when 
tested by Dr. Noriko Murase. gave superior results 
to those reported by Miyagawa et al. [16]; Miya-
gawa et al. had administered the drug intraperito-
neally rather than intravenously. Median survival of 
guinea pig hearts in rats was increased by a single 
dose of 200 mg/kg from 8 min to more than 8 hr, 
and in one experiment to more than a day [2]. The 
surprising potency of intravenous K76 by itself or 
in combination with the other drug FUT has also 
been demonstrated in the very difficult pig-to-dog 
kidney xenograft model. Survival out to 7 hr was 
obtained. during which 200 mg/hr of urine was pro-
duced. However, in both the rodent and large ani-
mal xenograft models, the effect was limited to a 
few hours. 
Brief control of the complement pathogenicity 
with any of the drugs or agents now available is not 
significant clinically. However, these drugs could be 
an adjunct to other strategies. One ancillary strat-
egy could be the production of transgenic animals 
whose organs contain transfected human genes that 
regulate complement activation. This was a subject 
of intense interest at the recent international xe-
notransplant meeting in Cambridge. 
Complement change after experimental liver transplantation 
The need to prevent complement activation may be 
short-term. particularly if the transplantation is of 
the liver. which is the principal source of the body's 
complement and the sole source of most comple-
ment components such as C3• A paper by Valdivia at 
the Cambridge meeting has potential importance 
because it has demonstrated the species restriction 
of complement [17J. 
In Valdivia's investigation. the combination of 
hamster liver and its complement plus the rat recipi-
ent equaled a rat transferred to a hamster comple-
ment environment (Fig. 2). Valdivia showed how. 
in the new complement environment. hyperacute 
rejection of stable liver and heart xenografts could 
be precipitated with a small dose intravenous anti-
hamster rat serum (Fig. 3). This was demonstrated 
to be a specific effect of the rat complement rather 
than the rat anti-hamster antibody because the hy-
peracute rejection could be completely avoided by 
simply heating the injected serum at 56°C for 30 
min (Fig. 3). This allowed retention of the rat anti-
hamster antibodies but removed the rat complement. 
This species restriction of complement is a discov-
ery that may be exploitable to facilitate xenograft 
acceptance. 
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Fig. 2. Demonstration by Valdivia et a!. [17] that the comple-
ment environment of a xenograft recipient becomes that of the 
donor species. In these experiments. the dominant complement 
of rat recipients of hamster livers become hamster-specific 
within a few days. a change that was permanent. See text for 
further explanation. 
Conclusions 
The xenograft barrier may be more vulnerable 
than most people realize at present. If comple-
ment activation proves to be the explanation, 
breaking this barrier whether it involves the clas-
sieal or alternative pathway may not be unrealis-
tic, Once this is achieved. it seems clear that 
conventional cellular and vascular rejection can 
be controlled with modern drug combinations. 
The complement reactions are the same as those 
that can abruptly destroy allografts. At present, 
the most intriguing question is whether the pro-
duction of transgenic animals whose organs have 
complement regulatory proteins (such as DAF and 
CD59) will be helpful. 
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1 ml anti-
hamster rat 
serum 
Fig. 3. Second stage experiments of Valdivia et al. (17) fol-
lowing the engrafunent shown in Figure 2. showing species 
restriction of complement activation. Rats bearing long surviv-
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